TherapeuticsMD, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Marlan D. Walker (CEO) and Joseph Ziegler (CFO) issued standard SOX 302 and 906 certifications on August 11, 2026 for the quarterly period ended June 30, 2026. The certifications affirm that the 10-Q contains no untrue material statements, that financial statements fairly present the company's condition, and that disclosure controls and internal controls over financial reporting are effective. No specific dollar amounts, transactions, or operational changes are detailed in these certification exhibits alone.
Why this rating
Routine SOX certification exhibits; standard periodic disclosure with no new material facts, transactions, or control failures reported.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.